

## **Appendixes**



## **Appendix A: Helpful Web Site Addresses**

The inclusion of Web sites in this appendix is intended to assist readers in finding additional information regarding the treatment of tobacco use and dependence and does not constitute endorsement of the contents of any particular site.

Addressing Tobacco in Managed Care: [www.aahp.org/atmc.htm](http://www.aahp.org/atmc.htm)

Agency for Healthcare Research and Quality: [www.ahrq.gov](http://www.ahrq.gov)

American Academy of Family Physicians: [www.aafp.org](http://www.aafp.org)

American Cancer Society: [www.cancer.org](http://www.cancer.org)

American Legacy Foundation: [www.americanlegacy.org](http://www.americanlegacy.org)

American Psychological Association: [www.apa.org](http://www.apa.org)

National Cancer Institute: [www.nci.nih.gov](http://www.nci.nih.gov)

National Center for Tobacco-Free Kids: [www.tobaccofreekids.org](http://www.tobaccofreekids.org)

National Guideline Clearinghouse: [www.guideline.gov](http://www.guideline.gov)

National Heart, Lung, and Blood Institute: [www.nhlbi.nih.gov/index.htm](http://www.nhlbi.nih.gov/index.htm)

National Institute on Drug Abuse: [www.nida.nih.gov/NIDAHome1.html](http://www.nida.nih.gov/NIDAHome1.html)

Office on Smoking and Health at the Centers for Disease Control and Prevention:  
[www.cdc.gov/tobacco](http://www.cdc.gov/tobacco)

Office on Smoking and Health at the Centers for Disease Control and Prevention:  
State highlights including lists of State tobacco control contacts: [www.cdc.gov/tobacco/statehi/statehi.htm](http://www.cdc.gov/tobacco/statehi/statehi.htm)

Society for Research on Nicotine and Tobacco: [www.srnt.org](http://www.srnt.org)

World Health Organization: [www.who.int](http://www.who.int)



# Appendix B: Coding Information Regarding the Diagnosis of and Billing for Tobacco Dependence Treatment

## Coding for the Treatment of Tobacco Use

Clinicians, clinic administrators, and health care delivery systems require appropriate diagnostic and billing codes for the documentation of reimbursement for tobacco dependence treatment. Information on such codes may help address a common clinical concern regarding the treatment of tobacco dependent patients: it is difficult to accurately document and obtain reimbursement for this treatment.

Although examples of such codes are provided below, clinicians and billing coders may use other diagnostic and reimbursement codes to document and obtain payment for this medical treatment. Additionally, it is incumbent on the clinician to ensure that appropriate billing guidelines are followed and to recognize that reimbursement of these codes may vary by payor or benefits package. For example, although psychiatric therapeutic codes appropriate for treating tobacco dependence exist, some payors or benefits packages have restrictions on mental health benefits. Similarly, reimbursement for preventive visits varies greatly among payors and benefits packages.

A systems-based approach will facilitate the understanding and use of such codes by clinicians. For example, various clinic or hospital meetings (e.g., business sessions, grand rounds, seminars, and coding in-service sessions) can explain and highlight the use of tobacco dependence codes for diagnosis and reimbursement. Additionally, these diagnostic codes can be preprinted on the billing and diagnostic coding sheets as a “check-off” rather than expect clinicians to recall and then manually document such treatment. Finally, clinicians can be reminded that counseling by itself is a reimbursable activity and can be billed for based on the number of minutes of counseling.

### 1. Diagnostic Codes (ICD-9-CM)

When clinicians provide treatment to patients dependent on tobacco, the following diagnostic codes can be used. They can be found in the ICD-9-CM (*International Classification of Diseases, 9<sup>th</sup> Revision, Clinical Modification*) coding manual under the section on Mental Disorders (290-319).

**305.1 Tobacco Use Disorder.** Cases in which tobacco is used to the detriment of a person’s health or social functioning or in which there is tobacco dependence. Dependent is included here rather than under drug dependence because tobacco differs from other drugs of dependence in its psychotropic effect.

## *Treating Tobacco and Dependence*

**Tobacco Dependence**—See Tobacco Use Disorder above. Excludes: History of tobacco use (V15.82).

**V15.82 History of Tobacco Use.** Excludes: Tobacco dependence (305.1).

## **2. Billing Codes**

A number of billing codes may be used for reimbursement of the provision of tobacco dependence treatment. The examples provided fall under the general categories of preventive medicine treatments and psychiatric therapeutic procedures.

**A. Preventive Medicine Treatments/Codes For Billing.** Preventive medicine treatment codes allow for the billing of counseling and other activities related to risk factor reduction interventions. Given the recognition of tobacco use as a causal risk factor for cancer, coronary artery disease, chronic obstructive pulmonary diseases, and others, these billing codes are appropriate when treating tobacco dependence. These codes can be billed on the basis of time spent (in minutes) counseling the tobacco dependent patient. As with other counseling billing requirements, the clinicians must indicate as part of the note the number of minutes counseled (CT) and the total number of minutes (TT) treating the patient.

For preventive medicine services, billing codes are distinguished based on the age of the patient, whether it is a new or established patient, whether the counseling is individual or group, whether the treatment was part of a comprehensive preventive medicine examination (**codes 99383-99387**), or whether it was specific preventive medicine counseling to intervene with the risk factor of tobacco dependence. These billing codes can be used for initial and followup treatments of tobacco use. For comprehensive preventive medicine examinations, the term “comprehensive” is not synonymous with the comprehensive examination requirements in the evaluation and management service codes (**90201-90350**).

### **A1. Tobacco Dependence Treatment As Part Of The Initial Or Periodic Comprehensive Preventive Medicine Examination**

#### **New Patient**

**99383** Initial preventive medicine evaluation and management of an individual, including a comprehensive history, a comprehensive examination, and counseling/anticipatory guidance, to treat the risk factor of tobacco use and the ordering of appropriate laboratory/diagnostic procedures. Late childhood (age 5-11 years)

**99384** Initial preventive medicine evaluation and management of an individual, including a comprehensive history, a comprehensive examination, and counseling/anticipatory guidance, to treat the risk factor of tobacco use and the ordering of appropriate laboratory/diagnostic procedures. Adolescent (age 12-17 years)

**99385** Initial preventive medicine evaluation and management of an individual, including a comprehensive history, a comprehensive examination, and counseling/anticipatory guidance, to treat the risk factor of tobacco use and the ordering of appropriate laboratory/diagnostic procedures. Adult (age 18-39 years)

**99386** Initial preventive medicine evaluation and management of an individual, including a comprehensive history, a comprehensive examination, and counseling/anticipatory guidance, to treat the risk factor of tobacco use and the ordering of appropriate laboratory/diagnostic procedures. Adult (age 40-64 years)

**99387** Initial preventive medicine evaluation and management of an individual, including a comprehensive history, a comprehensive examination, and counseling/anticipatory guidance, to treat the risk factor of tobacco use and the ordering of appropriate laboratory/diagnostic procedures. Adult (age 65 years and older)

#### **Established Patient**

**99393** Periodic preventive medicine re-evaluation and management of an individual, including a comprehensive history, comprehensive examination, and counseling/anticipatory guidance, to treat the risk factor of tobacco use and the ordering of appropriate laboratory/diagnostic procedures. Established patient, late childhood (age 5-11 years)

**99394** Periodic preventive medicine re-evaluation and management of an individual, including a comprehensive history, comprehensive examination, and counseling/anticipatory guidance, to treat the risk factor of tobacco use and the ordering of appropriate laboratory/diagnostic procedures. Established patient, adolescent (age 12-17 years)

**99395** Periodic preventive medicine re-evaluation and management of an individual, including a comprehensive history, comprehensive examination, and counseling/anticipatory guidance, to treat the risk factor of tobacco use and the ordering of appropriate laboratory/diagnostic procedures. Established patient, adult (age 18-39 years)

**99396** Periodic preventive medicine re-evaluation and management of an individual, including a comprehensive history, comprehensive examination, and counseling/anticipatory guidance, to treat the risk factor of tobacco use and the ordering of appropriate laboratory/diagnostic procedures. Established patient, adult (age 40-64 years)

**99397** Periodic preventive medicine re-evaluation and management of an individual, including a comprehensive history, comprehensive examination, and counseling/anticipatory guidance, to treat the risk factor of tobacco use and the

### *Treating Tobacco and Dependence*

ordering of appropriate laboratory/diagnostic procedures. Established patient, adult (age 65 years and older)

#### **A2. Tobacco Dependence Treatment as Specific Counseling and/or Risk Factor Reduction Intervention**

These codes are used to report services provided to individuals at a separate encounter for the purpose of promoting health and preventing illness or injury. As such, they are appropriate for the specific treatment of tobacco use and dependence. They are appropriate for initial or followup tobacco dependence treatments (new or established patient).

For the specific preventive medicine counseling codes, the number of minutes counseled determined the level of billing (**codes 99400-99404** for 15 to 60 minutes of counseling).

#### **Preventive Medicine, Individual Counseling**

**99401** Preventive medicine counseling and/or intervention to treat the risk factor of tobacco use provided to an individual (separate procedure); approximately 15 minutes.

**99402** Preventive medicine counseling and/or intervention to treat the risk factor of tobacco use provided to an individual (separate procedure); approximately 30 minutes.

**99403** Preventive medicine counseling and/or intervention to treat the risk factor of tobacco use provided to an individual (separate procedure); approximately 45 minutes.

**99404** Preventive medicine counseling and/or intervention to treat the risk factor of tobacco use provided to an individual (separate procedure); approximately 60 minutes.

#### **Preventive Medicine, Group Counseling**

**99411** Preventive medicine counseling and/or intervention to treat the risk factor of tobacco use provided to an individual (separate procedure); approximately 30 minutes.

**99412** Preventive medicine counseling and/or intervention to treat the risk factor of tobacco use provided to an individual (separate procedure); approximately 60 minutes.

**B. Psychiatric Therapeutic Procedures/Codes for Billing.** The psychiatric therapeutic procedure billing codes are typically used for insight-oriented, behavior modifying and/or supported psychotherapy. This refers to the development of



insight of affective understanding, the use of behavior modification techniques, the use of supportive interactions, the use of cognitive discussion of reality, or any combination of the above to provide therapeutic change. All of the counseling interventions for tobacco dependence demonstrated to be effective in this guideline would fall under these headings.

It should be noted that these billing codes can be modified for those patients receiving only counseling (psychotherapy) and for others that receive counseling (psychotherapy) and medical evaluation and management services. These evaluation and management services involve a variety of responsibilities unique to the medical management of psychiatric patients such as medical diagnostic evaluation (e.g., evaluation of comorbid medical conditions, drug interactions, and physical examinations), drug management when indicated, physician orders, and interpretation of laboratory or other medical diagnostic studies and observations. Thus, the use of a psychiatric therapeutic billing code with medical evaluation and management services would be appropriate for the clinician who provides both of the key tobacco dependence interventions documented as effective in the guideline: counseling and pharmacotherapy.

In documenting treatment for tobacco dependence using the psychiatric therapeutic procedure codes, the appropriate code is chosen on the basis of the type of psychotherapy (e.g., insight-oriented, behavior modifying, and/or supportive using verbal techniques), the place of service (office vs. inpatient), the face-to-face time spent with the patient during the treatment (both for psychotherapy and medication management), and whether evaluation and management services are furnished on the same date of service as psychotherapy.

#### **B1. Office or Other Outpatient Facility**

Insight-oriented, behavior modifying and/or supportive psychotherapy

**90804** Individual psychotherapy, insight-oriented, behavior modifying and/or supportive, in an office or outpatient facility, approximately 20 to 30 minutes face-to-face with the patient.

**90805** With medical evaluation and management services.

**90806** Individual psychotherapy, insight-oriented, behavior modifying and/or supportive, in an office or outpatient facility, approximately 45 to 50 minutes face-to-face with the patient.

**90807** With medical evaluation and management services.

**90808** Individual psychotherapy, insight-oriented, behavior modifying and/or supportive, in an office or outpatient facility, approximately 75 to 80 minutes face-to-face with the patient.

*Treating Tobacco and Dependence*

**90809** With medical evaluation and management services.

**B2. Inpatient Hospital, Partial Hospital, or Residential Care Facility**

Insight-oriented, behavior modifying and/or supportive psychotherapy

**90816** Individual psychotherapy, insight-oriented, behavior modifying and/or supportive, in an inpatient hospital, partial hospital, or residential care setting, approximately 20 to 30 minutes face-to-face with the patient.

**90817** With medical evaluation and management services.

**90818** Individual psychotherapy, insight-oriented, behavior modifying and/or supportive, in an inpatient hospital, partial hospital, or residential care setting, approximately 20 to 30 minutes face-to-face with the patient.

**90819** With medical evaluation and management services.

**90821** Individual psychotherapy, insight-oriented, behavior modifying and/or supportive, in an inpatient hospital, partial hospital, or residential care setting, approximately 20 to 30 minutes face-to-face with the patient.

**90822** With medical evaluation and management services.

**B3. Other Psychotherapy**

**90853** Group psychotherapy (other than a multiple-family group).

**B4. Dental Code**

**01320** Tobacco counseling for the control and prevention of oral disease.

## **Appendix C: Financial Disclosures for Panel Members, Consultants, and Senior Project Staff**

### **Panel Members**

Michael C. Fiore has served as a consultant for, given lectures sponsored by, or has conducted research sponsored by Ciba-Geigy, SmithKline Beecham, Lederle Laboratories, McNeil, Elan Pharmaceutical, and Glaxo Wellcome.

William C. Bailey has served as a consultant for, given lectures sponsored by, or has conducted research sponsored by Glaxo Wellcome, SmithKline Beecham, Schering-Plough, 3M Pharmaceuticals, Pfizer, and Sepracor.

Stuart J. Cohen has not served as a consultant for, given lectures sponsored by, or conducted research sponsored by any pharmaceutical company.

Sally Faith Dorfman has served as a consultant for, given lectures sponsored by, or has conducted research sponsored by various pharmaceutical companies.

Michael G. Goldstein, in addition to being an employee of the Bayer Corporation, has served as a consultant for, given lectures sponsored by, or has conducted research sponsored by Glaxo Wellcome, McNeil, Ciba-Geigy, SmithKline Beecham, Boehringer Ingelheim, Sano Corporation, Dupont Pharmaceuticals, and Eli Lilly.

Ellen R. Gritz has served as a consultant for, given lectures sponsored by, or has conducted research sponsored by Bristol Myers Squibb, SmithKline Beecham, and Glaxo Wellcome.

Richard B. Heyman has not served as a consultant for, given lectures sponsored by, or conducted research sponsored by any pharmaceutical company.

Carlos Roberto Jaén has served as a consultant for, given lectures sponsored by, or has conducted research sponsored by Glaxo Wellcome Pharmaceuticals.

Thomas E. Kottke has served as a consultant for, given lectures sponsored by, or has conducted research sponsored by McNeil Consumer Healthcare.

Harry A. Lando has served as a consultant for, given lectures sponsored by, or has conducted research sponsored by Glaxo Wellcome and SmithKline Beecham.

### *Treating Tobacco and Dependence*

Robert Mecklenburg has served as a consultant for, given lectures sponsored by, or has conducted research sponsored by SmithKline Beecham and Glaxo Wellcome.

Patricia Dolan Mullen has not served as a consultant for, given lectures sponsored by, or has conducted research sponsored by any pharmaceutical companies.

Louise M. Nett has not served as a consultant for, given lectures sponsored by, or conducted research sponsored by any pharmaceutical company.

Lawrence Robinson has not served as a consultant for, given lectures sponsored by, or conducted research sponsored by any pharmaceutical company.

Maxine L. Stitzer has served as a consultant for, given lectures sponsored by, or has conducted research sponsored by McNeil and SmithKline Beecham.

Anthony C. Tommasello has not served as a consultant for, given lectures sponsored by, or conducted research sponsored by any pharmaceutical company.

Louise Villejo has served as a consultant for, given lectures sponsored by, or has conducted research sponsored by Ortho Biotech.

Mary Ellen Wewers has not served as a consultant for, given lectures sponsored by, or conducted research sponsored by any pharmaceutical company.

## **Consultants**

Timothy Baker has served as a consultant for, given lectures sponsored by, or has conducted research sponsored by Elan Pharmaceutical, SmithKline Beecham, Glaxo Wellcome, and Lederle.

Victor Hasselblad has served as a consultant for, given lectures sponsored by, or has conducted research sponsored by CorTherapeutics, SkinCeuticals, Merck, Novartis, AstraZeneca, AstraCharnwood, The Medicines, Pfizer, Daiichi, Hoffman-LaRoche, RhonePolenc Rorer, Alexion, SmithKline Beecham, Dade, Quad-C, and Centocor Lilly.

Marc Manley has not served as a consultant for, given lectures sponsored by, or conducted research sponsored by any pharmaceutical company.

David L. Schriger has served as a consultant for, given lectures sponsored by, or has conducted research sponsored by Pfizer Corporation and the MedAmerica Corporation.

David W. Wetter has not served as a consultant for, given lectures sponsored by, or conducted research sponsored by any pharmaceutical company.

### **Senior Project Staff**

Brion J. Fox has not served as a consultant for, given lectures sponsored by, or has conducted research sponsored by any pharmaceutical company.



## Index

### A

Abstinence iii, iv, v, 3, 4, 9, 14, 17, 18, 20, 30, 31, 34, 35, 38, 42, 49, 51, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 92, 93, 95, 98, 100, 103, 104, 106, 108, 109, 111, 113, 114, 139, 140, 141, 143, 144, 145  
Acupuncture 51, 67, 70, 72, 139  
Adolescents xi, 3, 7, 21, 38, 39, 81, 91, 101, 102, 103, 105, 149  
Anxiolytics 78, 81  
Assessment 2, 3, 7, 8, 9, 10, 14, 21, 23, 25, 28, 37, 39, 42, 49, 51, 52, 53, 54, 55, 56, 64, 65, 93, 97, 100, 101, 112, 143, 145, 153  
followup 14, 39, 65, 95, 143  
specialized 54, 145  
Aversive smoking 38, 51, 66, 67, 139

### B

Benzodiazepines 78  
Biochemical confirmation 14, 18  
Bupropion SR 4, 26, 27, 30, 38, 39, 51, 71, 72, 78, 80, 82, 89, 94, 99, 100, 101, 102, 105, 106, 113, 114, 139  
Buspirone 78, 81

### C

Children xi, 3, 7, 21, 28, 32, 91, 93, 101, 102, 103, 149  
Clonidine iv, x, 4, 51, 71, 75, 76, 83, 88, 89, 90, 124, 129, 130, 140  
Combination nicotine replacement therapies 51, 65, 77, 78  
Community programs 62, 145  
Cost-effectiveness 11, 37, 42, 111, 112  
Counseling  
group 17, 18, 38, 39, 62, 63, 64, 141  
individual 18, 62, 63, 64, 141  
telephone 4, 39, 62, 64, 89, 97, 103, 104, 113, 141, 143, 146  
Cue exposure/extinction 140

### D

Diazepam 78, 140  
Disability 1, 7, 32, 98  
Duration of treatment 90

### E

Ethnic groups 97  
Exercise 67, 106, 107, 108, 112, 140  
Extra-treatment social support iv, 4, 30, 38, 39, 51, 66, 67, 140

### F

Focused smoking 139

### G

Gender 32, 91, 92  
Group counseling 17, 18, 62, 63, 64, 141

### H

Harm reduction xi, 3, 113, 114, 137  
Health care administrators iii, v, x, 1, 6, 8, 11, 20, 21, 42, 43  
Helpline 141, 144, 145  
Hospitalized smokers 3, 98  
Hotline 141, 144, 145  
Hypnosis 68, 70, 141

### I

Identifying smokers 53  
Insurance coverage 42  
Intent-to-treat analysis 141  
Intra-treatment social support iv, 4, 30, 51, 66, 67, 141

### L

Logistic regression 15, 16, 142

### M

Managed care 11, 41, 84, 112, 141, 142  
Mecamylamine 79, 81  
Minorities 3, 21, 96, 97, 98, 149  
Motivation to quit 3, 31, 32, 34, 55, 64, 65  
Motivational intervention 29, 31, 33, 54, 70, 96, 102, 144

## *Treating Tobacco and Dependence*

### **N**

Nasal spray 26, 27, 30, 39, 51, 71, 74, 77, 86, 89, 143  
Nicotine gum 26, 27, 30, 39, 51, 55, 71, 73, 77, 78, 80, 81, 83, 84, 89, 94, 105, 106, 109, 112  
Nicotine inhaler 71, 74  
Nicotine patch 26, 30, 39, 71, 74, 75, 77, 78, 79, 81, 84, 87, 88, 89, 90, 94, 97, 103, 109, 143, 146  
Nicotine replacement therapy 51, 77, 80, 85, 105, 142, 143  
Nortriptyline 4, 27, 71, 76, 78, 80, 83, 90, 99, 100, 101, 143

### **O**

Older smokers 3, 91, 103, 104  
Oral mucosa 84, 143  
Over-the-counter 5, 51, 73, 75, 84, 89, 90

### **P**

Person-to-person intervention 20, 51, 63, 143  
Pharmacotherapy 5, 10, 15, 18, 21, 26, 27, 30, 31, 33, 39, 41, 42, 43, 51, 54, 55, 60, 64, 65, 71, 72, 73, 74, 75, 76, 77, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 94, 96, 98, 99, 100, 103, 104, 108, 109, 111, 113, 140, 141, 143, 144, 171  
Placebo 10, 13, 19, 51, 67, 70, 71, 72, 73, 74, 75, 76, 78, 79, 84, 90  
Practical counseling 4, 30, 38, 39, 65, 66, 67, 68, 143  
Pregnant smokers 3, 82, 86, 87, 90, 91, 92, 93, 94  
Prescriptive interventions 34  
Prevalence 1, 7, 8, 14, 41, 97, 110, 112, 113, 143  
Primary care clinicians 20, 25, 112  
Propranolol 78, 143  
Psychiatric comorbidity 3, 100, 101  
Psychosocial interventions 38, 58, 92, 93, 94, 144

### **Q**

Quit date 13, 26, 29, 30, 31, 33, 82, 89, 90, 139, 140, 142  
Quit day 14, 88, 140, 144

### **R**

Rapid puffing 66, 139  
Rapid smoking 38, 66, 67, 94, 139, 144  
Reimbursement 6, 21, 111, 112, 167, 168  
Relapse 9, 10, 15, 25, 33, 34, 35, 51, 56, 64, 65, 66, 68, 71, 93, 95, 96, 99, 100, 101, 140, 143  
prevention 33, 34, 35, 64, 65, 66, 95, 96, 143

### **S**

Satiation smoking 139  
Screening 3, 5, 13, 15, 21, 23, 51, 52, 53, 54, 67, 68, 97, 111, 139  
Self-help treatment 13, 15, 17, 18, 39, 55, 60, 61, 62, 63, 64, 70, 84, 89, 91, 92, 94, 95, 97, 98, 103, 141, 144, 145  
Self-reported abstinence 14  
Serum cotinine 145  
Serum nicotine 54, 145  
Silver acetate 79, 145  
Skills training 4, 30, 65, 66, 67, 68, 143  
Smoke-free environment 99, 152  
Smokeless tobacco 32, 81, 91, 102, 108, 109, 151  
Smokeless tobacco users 91  
Smoking cessation specialists 8  
Social support 4, 30, 38, 39, 51, 65, 66, 67, 94, 95, 140, 141, 144  
Special populations 3, 11, 67, 91, 111, 152  
by age 30, 32, 91, 101, 103, 105, 108, 168, 169, 170  
by ethnicity 91, 105  
by hospitalized patients 21, 91, 98, 99, 111  
by pregnancy 7, 14, 32, 38, 39, 81, 82, 83, 85, 86, 87, 88, 90, 92, 93, 94, 95, 96, 151  
by race 91  
Specialists 35, 37, 65, 157



**T**

Training for clinicians 1, 3, 4, 6, 19, 21, 30,  
37, 65, 66, 67, 68, 109, 110, 143, 146, 147,  
151, 152

Transtheoretical Model 70, 71

Treatment matching 55, 70, 146

**V**

Vital signs 28, 52, 53, 140

**W**

Weight gain 3, 21, 26, 27, 33, 34, 80, 105,  
106, 107, 108, 146

Withdrawal symptoms 27, 30, 33, 39, 68,  
107



## Guideline Availability

This guideline is available in several formats suitable for health care practitioners, the scientific community, educators, and consumers.

The *Clinical Practice Guideline* presents recommendations for health care providers with brief supporting information, tables and figures, and pertinent references.

The *Quick Reference Guide* is a distilled version of the clinical practice guideline, with summary points for ready reference on a day-to-day basis.

The *Consumer Version* is an information booklet for the general public to increase consumer knowledge and involvement in health care decisionmaking.

To order single copies of these guideline products, the meta-analyses reference list, or to obtain further information on the availability of other derivative products, call the Publications Clearinghouse toll-free at 800-358-9295 or write to: Publications Clearinghouse, P.O. Box 8547, Silver Spring, MD 20907.

## Notes